Kazia Therapeutics Limited (KZIA) Stock Is Rising Now

March 14, 2018 - By Adrian Erickson

The stock of Kazia Therapeutics Limited (NASDAQ:KZIA) is a huge mover today! The stock increased 4.79% or $0.28 during the last trading session, reaching $6.12. About 116,149 shares traded or 264.07% up from the average. Kazia Therapeutics Limited (NASDAQ:KZIA) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 5 months positive chart setup for the $29.66M company. It was reported on Mar, 14 by Barchart.com. We have $6.43 PT which if reached, will make NASDAQ:KZIA worth $1.48M more.

More notable recent Kazia Therapeutics Limited (NASDAQ:KZIA) news were published by: Benzinga.com which released: “46 Biggest Movers From Yesterday” on February 26, 2018, also Benzinga.com with their article: “24 Stocks Moving In Friday’s Pre-Market Session” published on February 23, 2018, Marketwatch.com published: “Living Cell Technologies Ltd. ADR” on March 30, 2015. More interesting news about Kazia Therapeutics Limited (NASDAQ:KZIA) were released by: Benzinga.com and their article: “40 Stocks Moving In Friday’s Mid-Day Session” published on February 23, 2018 as well as Benzinga.com‘s news article titled: “32 Biggest Movers From Yesterday” with publication date: March 06, 2018.

Kazia Therapeutics Limited, a biotechnology company, develops anti-cancer drugs. The company has market cap of $29.66 million. It has three technologies, which include phosphoinositide 3-kinase inhibitors, superbenzopyran, and anti-tropomyosin. It currently has negative earnings. The firm is developing GDC-0084, a novel targeted therapy that has completed Phase I clinical trial for the treatment of glioblastoma; Cantrixil, which is in Phase I clinical trials to treat ovarian cancer; and Trilexium, a novel therapy that is in early stage pre-clinical development for the treatment of various cancer types.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.